Dave Fredrickson was appointed Executive Vice-President, Oncology Business Unit (OBU) in October 2017 and is responsible for driving growth and maximizing the commercial performance of the AstraZeneca global oncology portfolio. In addition, Dave plays a critical leadership role defining and delivering the oncology strategy for the company with accountability for marketing, sales, medical affairs and market access both globally and in major markets.
Since joining AstraZeneca in 2014, Dave has held several leadership positions of increasing responsibility, including Vice President, Specialty Care for AstraZeneca in the United States and President of AstraZeneca K. K. in Japan. During his time in Japan, Dave also served as Vice Chairman of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan and was a member of the Board of Directors for the Japan Pharmaceutical Manufacturers Association (JPMA). Before joining AstraZeneca, Dave worked at Roche/Genentech, where he served in several functions and leadership positions, including Oncology Business Unit Manager in Spain and strategy, marketing and sales roles in the US. Before joining Roche/Genentech, Dave worked at the Monitor Group, LLC (now Monitor Deloitte Group, LLC), a global strategy consultancy. Dave is a graduate of Georgetown University in Washington, DC.
